A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis

Keyphrases

• Randomized Placebo-controlled Trial 100%
• Multiple Sclerosis 100%
• Phase II Trial 100%
• Laquinimod 100%
• Control Phase 100%
• Placebo 58%
• Interferon beta-1a 41%
• Annualized Relapse Rate 33%
• Expanded Disability Status Scale 25%
• Brain Volume Changes 25%
• Confirmed Disability Worsening 25%
• Hazard Ratio 16%
• Once-daily 16%
• Risk Ratio 16%
• Multiple Sclerosis Functional Composite 16%
• Relapsing-remitting MS 16%
• Adverse Events 8%
• Placebo-controlled 8%
• Brain Atrophy 8%
• Disability Progression 8%
• Once-weekly 8%
• MS Patients 8%
• Disability Worsening 8%
• Avonex 8%
• Well Tolerated 8%

Immunology and Microbiology

• Multiple Sclerosis 100%
• Laquinimod 100%
• Interferon Beta 1a 50%
• Expanded Disability Status Scale 25%
• Brain Size 25%
• Multiple Sclerosis Functional Composite 16%
• Arm 8%